U.S. Markets closed

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2000-0.0400 (-3.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2400
Open1.2400
Bid1.1900 x 1800
Ask1.2200 x 2200
Day's Range1.1700 - 1.2700
52 Week Range0.9900 - 3.7900
Volume766,776
Avg. Volume1,067,073
Market Cap119.871M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.5590
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Abeona Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences: Citi’s 16th Annual BioPharma Virtual Conference on September 8-10, 2021 (one-on-one meetings only).H.C. Wainwright 23rd Annual Global Investment Conference. The pre-recorded presentation will be avai

  • GlobeNewswire

    Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

    NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had served as Abeona’s Chief Accounting Officer since January 2019. “I look forward to working together with Ed to meet our near-term clinical and regulatory milestones, as well as set Abeona on a course for lo

  • GlobeNewswire

    Abeona Therapeutics Reports Second Quarter Financial Results

    Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA; Alignment with FDA on primary study endpoint Focusing resources on completing EB-101 and ABO-102 pivotal, registration-enabling studies Conference call scheduled for Thursday, July 29, 2021 at 8:30 a.m. ET NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a